Biocortech and Drug Safety Executive Council announce Technology Evaluation Consortium to Validate Novel Toxicogenomic Screening Assay to Predict Potential Drug-Induced Psychiatric Adverse Events
June 17, 2010 – Paris, France and Needham, MA, USA
Biocortech, Paris Biopark, Paris, France and Drug Safety Executive Council (DSEC), Needham, Massachusetts, United States- June 17, 2010 - Biocortech, the biopharmaceutical company dedicated to the development of drug safety screening assays and in vitro blood tests for neuropsychiatric disorders, and DSEC ( Drug Safety Executive Council) today announced that they entered into a Technology Evaluation Consortium. "We are very proud of having been selected for such an exclusive partnership that allows a limited number of cutting-edge technology and services providers to work with DSEC," said Dinah Weissmann, Biocortech’s founder and CEO. This partnership, which is aimed at validating Biocortech’s toxicogenomic screening assay for predicting potential drug-induced neuropsychiatric adverse events, recently entered into the operational phase with five leading pharmaceutical companies whose names are undisclosed. "This is a tremendous opportunity to establish Biocortech within the DSEC community as a leading expert and service provider," added Frederic Allemand, Biocortech’s CBO.
"The Biocortech technology platform and service offering dovetails with DSEC’s objective of improving the overall economics of R&D and advancing the development of better and safer medicines. This is an exciting project for both our team and our participating pharma members," said Eric Glazer, Managing Director of DSEC.
About Biocortech
Biocortech is a biopharmaceutical company committed to the discovery and development of novel biomarkers and treatments for neuropsychiatric disorders such as depression, bipolar disorders, schizophrenia and cognitive deficits. Biocortech’s proprietary drug cellular screening assays and blood tests can contribute respectively to de-risking and optimizing drug candidates with respect to potential drug-induced psychiatric adverse events, and to personalizing psychiatric medicine. Biocortech is based in Paris, France.
About Drug Safety Executive Council
DSEC is a peer membership of over 2,000 drug safety leaders with the common objective of advancing the development of better and safer medicines. DSEC also manages a Technology Evaluation Consortium, made up of multiple biopharmaceutical companies, that qualifies novel, preclinical safety platforms. Learn more at www.drugsafetycouncil.org. DSEC’s mission is to create a forum that enables constituents to improve drug development paradigms by integrating a select few technology and service providers into the DSEC community through its Technology Evaluation Consortium. DSEC is managed by Cambridge Healthtech Associates (CHA), the leading organizer and facilitator of consortia and communities in the life sciences industry. CHA is a wholly owned subsidiary of Cambridge Healthtech Institute (CHI).